Akari Therapeutics, Plc Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Akari Therapeutics, Plc (AKTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2025-08-13
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2025-06-30 | 0.00% 10-Q · filed 2025-08-13 | |||
| 2024-06-30 | 0.00% 10-Q · filed 2025-08-13 | |||
| 2023-12-31 | 0.00% 8-K · filed 2024-09-06 | |||
| 2022-12-31 | 0.00% 8-K · filed 2024-09-06 | |||
| 2022-06-30 | 0.00% 6-K · filed 2022-09-27 | |||
| 2022-03-10 | 0.00% 20-F · filed 2023-05-01 | |||
| 2022-01-04 | 0.00% 20-F · filed 2023-05-01 | |||
| 2021-12-31 | 0.00% 20-F · filed 2023-05-01 | |||
| 2021-06-30 | 0.00% 6-K · filed 2021-09-22 | |||
| 2020-12-31 | 0.00% 20-F · filed 2023-05-01 | |||
| 2020-06-30 | 0.00% 6-K · filed 2020-09-01 | |||
| 2019-12-31 | 0.00% 20-F · filed 2022-05-16 | |||
| 2019-06-30 | 0.00% 6-K · filed 2020-09-01 | |||
| 2018-12-31 | 0.00% 20-F · filed 2021-04-21 | |||
| 2018-06-30 | 0.00% 6-K · filed 2019-08-29 | |||
| 2017-12-31 | 0.00% 20-F · filed 2020-03-31 | |||
| 2017-06-30 | 0.00% 6-K · filed 2018-09-27 | |||
| 2016-12-31 | 0.00% 20-F · filed 2019-04-23 | |||
| 2011-03-31 | 0.00% 20-F · filed 2014-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |